A method for removing host DNA from metagenomes using highly specific guide RNA and CRISPR-dCas9
By designing 18nt-length high-specific crRNA and sgRNA targeting Alu and L1 elements, combining dCas9 protein to form RNP complex, the non-specific and high-cost problems of removing human DNA in the prior art are solved, and high efficiency and low cost are achieved the effect of host DNA removal.
Patent Information
- Application Number
- CN202311848717.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-29
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2043-12-29
AI Technical Summary
The existing CRISPR-dCas9 dehosting method has high nonspecificity, resulting in microbial loss, and the sgRNA design is complex and costly, making it difficult to meet the needs of efficiently removing human DNA.
A highly specific crRNA sequence with a length of 18 nt was designed, sgRNA was designed for Alu and L1 element conserved sequences, and combined with dCas9 protein to form an RNP complex, and the host DNA was removed through magnetic bead capture, improving removal efficiency and specificity.
It realizes high specificity and efficiency removal of host DNA, reduces microbial losses, simplifies the sgRNA design and synthesis process, and reduces costs.
Smart Images

Figure CN117947027B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedical technology, and in particular, relates to a method for removing host DNA in a metagenome by using highly specific guide RNA and CRISPR-dCas9. Background Art
[0002] The Clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (Cas9) system is a defense mechanism for bacteria against phage infection. Its working principle is that under the mediation of guide RNA (gRNA), Cas9 binds to the target DNA and performs double-stranded cleavage of the target DNA. The binding of Cas9 to the target DNA only occurs when the PAM (protospacer adjacent motif) sequence is present and the 17-20 bases on the complementary strand adjacent to the PAM are complementary to the gRNA. For applications that do not require DNA cleavage, the endonuclease active site of Cas9 has been mutated to obtain dCas9 (dead Cas9), which still has the ability to bind to DNA. The CRISPR-dCas9 system has been widely used in studies such as transcriptional regulation, genome imaging, and DNA capture.
[0003] Metagenomic sequencing (mNGS) is a technology for unbiased detection of pathogenic microorganisms in clinical samples. A major challenge faced by this technology is the presence of a large amount of host nucleic acids in the metagenomic samples to be detected. These host nucleic acids not only account for the vast majority of sequencing data during the sequencing process, resulting in waste, but also reduce the detection sensitivity of microorganisms. Therefore, removing host DNA from metagenomic samples has become a key technology to improve the sensitivity of metagenomic detection and reduce sequencing costs. The commonly used host removal method is differential lysis. Most bacteria and fungi have cell wall structures that are stronger than human cell membranes. Therefore, using a milder lysis buffer can achieve lysis of human cells while retaining the integrity of most microorganisms. After digesting the human genomic DNA released by lysis with DNase, the microbial genome can be extracted with a lysis buffer with a higher lysis intensity, thereby achieving the purpose of removing host DNA. The advantage of this method is simple operation, and the disadvantage is that it has a large preference, a high recovery rate for microorganisms that are difficult to lyse, and a large loss of microorganisms that are easy to lyse and in poor condition.
[0004] Unlike the differential lysis method, the removal of human DNA from the extracted metagenomic samples using the CRISPR-dCas9 method can effectively avoid the loss of microbial DNA. This method is simple to operate, highly specific, has no microbial preference, and is basically unaffected by the sample state. However, the sgRNA used in the existing CRISPR-dCas9 host removal method has a sequence (crRNA) length of 20nt that binds to DNA. Due to the high error tolerance of the two bases at the 5' end of the 20nt crRNA, the current method has high non-specificity and is prone to microbial loss; in addition, the DNA targeted by the sgRNA in the current method is a sequence with a certain interval on the whole genome or an Alu element. The former has a wide coverage of the genome but requires a large number of sgRNAs, resulting in cumbersome design, synthesis, preparation and quality inspection of sgRNA and high cost. The latter has limited coverage of the genome, which will affect the removal efficiency of host DNA, that is, the sgRNA used in the current method cannot meet the requirements of controlling costs while obtaining a high human-removal efficiency. Summary of the invention
[0005] In view of this, in order to overcome the above-mentioned technical problems existing in the art, the purpose of the present invention is to provide a method for removing host DNA from a metagenome using a highly specific guide RNA and CRISPR-dCas9. In order to improve the specificity of the existing CRISPR-dCas9 method for removing host DNA, the present invention designs a crRNA sequence with high specificity and a length of 18nt (two bases less than the 5' end of the 20nt crRNA); in addition, in order to take into account the cost and efficiency of the CRISPR-dCas9 host removal method, the present invention designs sgRNA for the conserved sequences of primate-specific Alu and L1 (L1PA) elements that are widely distributed in the human genome and have complementary characteristics at the distribution sites.
[0006] In order to achieve the above object, the present invention adopts the following technical solutions:
[0007] The first aspect of the present invention provides a set of sgRNAs with high specificity and high host DNA removal efficiency.
[0008] Further, the sgRNA includes Alu_trusgRNA targeting Alu and / or L1_trusgRNA targeting L1;
[0009] The Alu_trusgRNA is Alu_trusgRNA_1~Alu_trusgRNA_8;
[0010] The L1_trusgRNA is L1_trusgRNA_1 to L1_trusgRNA_8;
[0011] The sequences of Alu_trusgRNA_1 to Alu_trusgRNA_8 are shown in SEQ ID NOs: 17 to 24;
[0012] The sequences of L1_trusgRNA_1 to L1_trusgRNA_8 are shown in SEQ ID NOs: 25 to 32.
[0013] In the present invention, the sgRNA (single guide RNA) refers to a single guide RNA, which is a molecular tool commonly used in genetic engineering. sgRNA is obtained by modifying crRNA (CRISPR RNA) and tracrRNA (transactivating CRISPR RNA) through genetic engineering. sgRNA can be complementary to the target DNA sequence, forming RNA-DNA hybridization, and then activating the Cas9 (CRISPR-associated protein 9) enzyme.
[0014] In a specific embodiment of the present invention, the primer sequences required for preparing the sgRNA described in the first aspect of the present invention are respectively shown as SEQ ID NOs: 34 to 66, and the template sequence required for preparing the sgRNA described in the first aspect of the present invention is shown as SEQ ID NO: 33.
[0015] A second aspect of the present invention provides a sgRNA-dCas9 complex.
[0016] Further, the sgRNA-dCas9 complex comprises the sgRNA described in the first aspect of the present invention;
[0017] Preferably, the sgRNA-dCas9 complex further comprises dCas9, 10X NEB buffer, and RNaseinhibitor;
[0018] More preferably, the usage amounts of Alu_trusgRNA, L1_trusgRNA, dCas9, 10X NEB buffer, and RNaseinhibitor are (0.1-0.5) μg, (0.1-0.5) μg, (0.1-1) μg, (0.5-1.5) μL, (0.1-1) μL, and (5-15) μL, respectively;
[0019] Most preferably, the usage amounts of Alu_trusgRNA, L1_trusgRNA, dCas9, 10X NEB buffer, and RNaseinhibitor are 0.25 μg, 0.25 μg, 0.5 μg, 1 μL, 0.5 μL, and 10 μL, respectively;
[0020] Most preferably, the sgRNA-dCas9 complex is supplemented with NFW to 10 μL.
[0021] In the present invention, the dCas9 (dead Cas9) is a mutant of the Cas9 protein, which is obtained by performing amino acid mutations on the two nuclease domains of RuvC (D10A) and NHN (H840A), respectively, to obtain a Cas9 protein without nuclease activity, so that it loses the function of cutting DNA, but still retains the ability to bind DNA. Such Cas9 is called dCas9. Currently, the CRISPR-dCas9 system is commonly used for genome transcription regulation to activate or inhibit the expression of specific genes, thereby achieving the purpose of studying gene function.
[0022] In a specific embodiment of the present invention, in order to improve the specificity of the CRISPR-dCas9 system in removing human DNA, the present invention designed crRNAs with lengths of 18nt and 20nt for Alu, and synthesized trusgRNA (truncated single-guide RNA) and sgRNA with lengths of 98nt by in vitro transcription. The two lengths of sgRNA were respectively assembled with dCas9 protein into RNP complexes. After performing host removal experiments with the two complexes, the host removal efficiency of the two complexes was detected by qPCR. The results showed that compared with the 100nt sgRNA, there was basically no microbial loss in the 98nt sgRNA host removal.
[0023] In a specific embodiment of the present invention, in order to further achieve effective removal of the human genome, the present invention designs trusgRNA and sgRNA with lengths of 98nt and 100nt respectively for the conserved sequences of Alu and L1 (L1PA), and synthesizes Alu-sgRNA, L1-sgRNA, Alu-trusgRNA, and L1-trusgRNA, and assembles them into RNP complexes with dCas9 respectively. After performing host removal experiments with different combinations of RNP complexes, the host removal efficiency of different sgRNA combinations was detected by qPCR, and the results showed that the use of trusgRNA targeting both Alu and L1 had a higher host removal efficiency than the use of sgRNA targeting Alu or L1 alone.
[0024] The third aspect of the present invention provides a reagent for removing host DNA in a metagenome with high specificity and efficiency.
[0025] Furthermore, the reagent comprises the sgRNA-dCas9 complex described in the second aspect of the present invention.
[0026] In some embodiments, the reagents described in the present invention may also include any other reagents that are beneficial to removing host DNA from the metagenome.
[0027] The fourth aspect of the present invention provides a product for removing host DNA from a metagenome with high specificity and efficiency.
[0028] Furthermore, the product comprises the reagent described in the third aspect of the present invention.
[0029] Furthermore, the product includes a kit.
[0030] In some embodiments, the kit is used to remove host DNA from a metagenome with high specificity and efficiency.
[0031] The fifth aspect of the present invention provides a method for removing host DNA in a metagenome using highly specific sgRNA and CRISPR-dCas9.
[0032] Further, the method comprises the following steps:
[0033] (1) extracting total metagenomic nucleic acid from a sample derived from a host to obtain a metagenomic nucleic acid sample containing host genomic DNA;
[0034] (2) preparing an sgRNA-dCas9 complex, wherein the sgRNA-dCas9 complex comprises the Alu_trusgRNA and / or L1_trusgRNA and dCas9 described in the first aspect of the present invention;
[0035] (3) preparing a reaction system, wherein the reaction system comprises the nucleic acid sample described in step (1) and the sgRNA-dCas9 complex described in step (2), and reacting in a buffer;
[0036] (4) Using magnetic beads coated with streptavidin to capture the sgRNA-dCas9 complex and its bound host DNA to form a magnetic bead-protein-RNA-DNA complex;
[0037] (5) Magnetic separation removes the magnetic bead-protein-RNA-DNA complex, thereby achieving the purpose of removing host DNA from the metagenome.
[0038] Furthermore, the sgRNA-dCas9 complex in step (2) further includes dCas9, 10X NEB buffer, and RNase inhibitor;
[0039] Preferably, the usage amounts of Alu_trusgRNA, L1_trusgRNA, dCas9, 10X NEB buffer, and RNaseinhibitor are (0.1-0.5) μg, (0.1-0.5) μg, (0.1-1) μg, (0.5-1.5) μL, (0.1-1) μL, and (5-15) μL, respectively;
[0040] More preferably, the usage amounts of Alu_trusgRNA, L1_trusgRNA, dCas9, 10X NEB buffer, and RNaseinhibitor are 0.25 μg, 0.25 μg, 0.5 μg, 1 μL, 0.5 μL, and 10 μL, respectively;
[0041] Most preferably, the sgRNA-dCas9 complex is supplemented with NFW to 10 μL.
[0042] Furthermore, the reaction system in step (3) is composed of the following: nucleic acid sample, sgRNA-dCas9 complex, 10XNEB buffer;
[0043] Preferably, the usage amounts of the nucleic acid sample, sgRNA-dCas9 complex, and 10X NEB buffer are (5-15) ng, (0.5-1.5) μL, and (0.5-3.5) μL, respectively;
[0044] More preferably, the nucleic acid sample, sgRNA-dCas9 complex, and 10X NEB buffer are used in amounts of 10 ng, 1 μL, and 2 μL, respectively;
[0045] Most preferably, the reaction system is supplemented with NFW to 20 μL.
[0046] Furthermore, the magnetic beads coated with streptavidin in step (4) are M-270 streptavidin magnetic beads.
[0047] In some embodiments, the host described in the present invention is a human, and the nucleic acid sample is extracted from human whole blood, plasma, serum, tears, saliva, alveolar lavage fluid, pleural effusion, ascites, drainage fluid, pus, mucus, cerebrospinal fluid, other puncture fluid, teeth, bones, nails, feces, urine, other tissues or biopsy samples, etc. The host DNA is a type of host nucleic acid, including all human chromosomal DNA, and is not interrupted by artificial mechanical methods or treated with fragmentation enzymes, and is a double-stranded nuclear DNA with good integrity.
[0048] The sixth aspect of the present invention provides the use of the sgRNA described in the first aspect of the present invention, the sgRNA-dCas9 complex described in the second aspect of the present invention, the reagent described in the third aspect of the present invention, or the product described in the fourth aspect of the present invention in removing host DNA in a metagenome using CRISPR-dCas9.
[0049] Compared with the prior art, the present invention has the following advantages and beneficial effects:
[0050] In order to improve the specificity of CRISPR-dCas9 system in removing human DNA, the present invention designed crRNAs with lengths of 18nt and 20nt for Alu, and synthesized trusgRNAs with lengths of 98nt (Alu_trusgRNA and L1_trusgRNA, if the first base at the 5' end of sgRNA is not G, a G needs to be added to the 5' end, and the length of such sgRNA is 99nt) and sgRNAs with lengths of 100nt (Alu_sgRNA and L1_sgRNA, if the first base at the 5' end of sgRNA is not G, a G needs to be added to the 5' end, and the length of such sgRNA is 101nt) by in vitro transcription, and the sgRNAs of the two lengths were respectively assembled into RNP complexes with dCas9 proteins, and then the host removal experiments were carried out with the two complexes, and the host removal efficiency of the two complexes was detected by qPCR. The results showed that compared with the 100nt sgRNA, there was basically no loss of microorganisms in the host removal of the 98nt sgRNA, indicating that the present invention has achieved unexpected technical effects. The method provided by the present invention improves the specificity and efficiency of the CRISPR-dCas9 host DNA removal method while ensuring the low cost of the method. BRIEF DESCRIPTION OF THE DRAWINGS
[0051] Figure 1 : Host removal effects of sgRNAs of different lengths, where the complementary sequence length of Alu_sgRNA and DNA is 20 nt, and the complementary sequence length of Alu_trusgRNA and DNA is 18 nt, * indicates t-test p<0.05, ** indicates t-test p<0.01; Figure 2 : Comparison of the host removal effects of trusgRNA targeting Alu and L1 and sgRNA targeting Alu or L1, where * indicates t-test p<0.05, and ** indicates t-test p<0.01. DETAILED DESCRIPTION
[0052] The present invention is further described below in conjunction with specific examples, which are only used to explain the present invention and are not to be construed as limiting the present invention. It will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to these embodiments without departing from the principles and purposes of the present invention, and that the scope of the present invention is defined by the claims and their equivalents. The experimental methods for which specific conditions are not specified in the following examples are usually tested under conventional conditions or under conditions recommended by the manufacturer.
[0053] Example 1 Comparison of host removal effects of sgRNAs of different lengths
[0054] 1. Experimental Materials
[0055] High-Fidelity 2X PCR Master Mix,NEB;
[0056] HiScribe TM T7 Quick High Yield RNA Synthesis Kit,NEB;
[0057] dCas9-3xFLAG-Biotin Protein,Sigma-Aldrich;
[0058] Dynabeads TM M-270 streptavidin, ThermoFisher;
[0059] RNA Clean&Concentrator-5,ZYMO RESEARCH;
[0060] RNase Inhibitor, NEB;
[0061] NEBuffer,NEB;
[0062] Probe qPCR Mix, Takara.
[0063] 2. Experimental methods
[0064] (1) Alu_sgRNA mixture (including Alu_sgRNA_1 to Alu_sgRNA_8, see Table 1) and Alu_trusgRNA mixture (including Alu_trusgRNA_1 to Alu_trusgRNA_8, see Table 1) were synthesized by in vitro transcription. The primers and templates required for preparing the sgRNA are shown in Table 2.
[0065] Table 1 sgRNA sequences
[0066]
[0067]
[0068] Table 2 Primers and templates required for preparing sgRNA
[0069]
[0070]
[0071] (2) Two sgRNA-dCas9 complexes were prepared: the composition of complex one is shown in Table 3, and the composition of complex two is shown in Table 4.
[0072] Table 3 Complex 1
[0073]
[0074] Table 4 Complex II
[0075]
[0076] (3) Prepare nucleic acid standards with 90% human origin and 5% each of Acinetobacter baumannii and Klebsiella pneumoniae.
[0077] (4) Prepare the three reaction systems shown in Table 5 below: The sgRNA-dCas9 complexes used in the two experimental groups are the two complexes assembled in Table 3 and Table 4, respectively.
[0078] Table 5 Three reaction systems
[0079]
[0080] (5) Corresponding to the three groups of reaction products, take 10 μL of M-270 streptavidin magnetic beads and wash the beads twice with 50 μL 1X NEB buffer.
[0081] (6) Resuspend the magnetic beads with 20 μL of the product, rotate and bind at room temperature for 5-10 min, recover the supernatant, and repeat the process three times.
[0082] (7) The recovered product was used for qPCR detection. The qPCR reaction system and program settings are shown in Table 6 below.
[0083] Table 6 qPCR reaction system and program settings
[0084]
[0085] 3. Experimental results
[0086] The results are as follows Figure 1As shown, the complementary sequence length between Alu_sgRNA and DNA is 20nt, and the complementary sequence length between Alu_trusgRNA and DNA is 18nt. The results show that trusgRNA has higher specificity (less loss of Klebsiella pneumoniae) and higher host removal efficiency than sgRNA, indicating that the trusgRNA used in the present invention has achieved unexpected technical effects.
[0087] Example 2 Comparison of host removal effects of different combinations of sgRNA
[0088] 1. Experimental Materials
[0089] High-Fidelity 2X PCR Master Mix,NEB;
[0090] HiScribe TM T7 Quick High Yield RNA Synthesis Kit,NEB;
[0091] dCas9-3xFLAG-Biotin Protein,Sigma-Aldrich;
[0092] Dynabeads TM M-270 streptavidin, ThermoFisher;
[0093] RNA Clean&Concentrator-5,ZYMO RESEARCH;
[0094] RNase Inhibitor, NEB;
[0095] NEBuffer,NEB;
[0096] Probe qPCR Mix, Takara.
[0097] 2. Experimental methods
[0098] (1) Alu_sgRNA mixture (including Alu_sgRNA_1 to Alu_sgRNA_8, see Table 1), L1_sgRNA mixture (including L1_sgRNA_1 to L1_sgRNA_8, see Table 1), Alu_trusgRNA mixture (including Alu_trusgRNA_1 to Alu_trusgRNA_8, see Table 1), and L1_trusgRNA mixture (including L1_trusgRNA_1 to L1_trusgRNA_8, see Table 1) were synthesized by in vitro transcription.
[0099] (2) Three sgRNA-dCas9 complexes were prepared: the composition of complex one is shown in Table 7, the composition of complex two is shown in Table 8, and the composition of complex three is shown in Table 9.
[0100] Table 7 Complex 1
[0101]
[0102] Table 8 Complex II
[0103]
[0104] Table 9 Complex III
[0105]
[0106] (3) Prepare nucleic acid standards with 90% human origin and 5% each of Acinetobacter baumannii and Klebsiella pneumoniae.
[0107] (4) Prepare the four reaction systems shown in Table 10 below: The sgRNA-dCas9 complexes used in the three experimental groups are the three complexes assembled in Tables 7-9, respectively.
[0108] Table 10 4 reaction systems
[0109]
[0110] (5) Take 10 μL of M-270 streptavidin magnetic beads from each of the four reaction products and wash the beads twice with 50 μL 1X NEB buffer.
[0111] (6) Resuspend the magnetic beads with 20 μL of the product, rotate and bind at room temperature for 5-10 min, recover the supernatant, and repeat the process three times.
[0112] (7) The recovered product was used for qPCR detection. The qPCR reaction system and program settings are shown in Table 11 below.
[0113] Table 11 qPCR reaction system and program settings
[0114]
[0115] 3. Experimental results
[0116] The results are as follows Figure 2 As shown, the results showed that the use of trusgRNA targeting Alu and L1 could effectively improve the host removal efficiency compared with the use of sgRNA targeting Alu or L1 alone.
Claims
1. A group of sgRNAs with high specificity and high host DNA removal efficiency, characterized in that: The sgRNA includes Alu_trusgRNA targeting Alu or a combination of Alu_trusgRNA targeting Alu and L1_trusgRNA targeting L1; The Alu_trusgRNA is Alu_trusgRNA_1~Alu_trusgRNA_8; The L1_trusgRNA is L1_trusgRNA_1 to L1_trusgRNA_8; The sequences of Alu_trusgRNA_1 to Alu_trusgRNA_8 are shown in SEQ ID NOs: 17 to 24; The sequences of L1_trusgRNA_1 to L1_trusgRNA_8 are shown in SEQ ID NOs: 25 to 32.
2. A sgRNA-dCas9 complex, characterized in that The sgRNA-dCas9 complex comprises the sgRNA of claim 1.
3. The sgRNA-dCas9 complex according to claim 2, characterized in that The sgRNA-dCas9 complex further comprises dCas9, 10X NEB buffer, and RNase inhibitor.
4. The sgRNA-dCas9 complex according to claim 3, characterized in that The usage amounts of Alu_trusgRNA, L1_trusgRNA, dCas9, 10X NEB buffer, and RNase inhibitor are (0.1~ 0.5) μg, (0.1~ 0.5) μg, (0.1~ 1) μg, (0.5~ 1.5) μL, and (0.1~ 1) μL, respectively.
5. The sgRNA-dCas9 complex according to claim 4, characterized in that The usage amounts of Alu_trusgRNA, L1_trusgRNA, dCas9, 10X NEB buffer, and RNase inhibitor were 0.25 μg, 0.25 μg, 0.5 μg, 1 μL, and 0.5 μL, respectively.
6. The sgRNA-dCas9 complex according to claim 5, characterized in that The sgRNA-dCas9 complex was supplemented with NFW to 10 μL.
7. A highly specific and efficient reagent for removing host DNA from a metagenome, characterized in that: The reagent comprises the sgRNA-dCas9 complex according to any one of claims 2 to 6.
8. A product for removing host DNA from metagenomes with high specificity and efficiency, characterized in that: The product comprises the reagent of claim 7.
9. The product according to claim 8, characterized in that The products include kits.
10. A method for removing host DNA from a metagenome using highly specific sgRNA and CRISPR-dCas9, characterized in that: The method comprises the following steps: (1) extracting total metagenomic nucleic acid from a sample derived from a host to obtain a metagenomic nucleic acid sample containing host genomic DNA; (2) preparing a sgRNA-dCas9 complex, wherein the sgRNA-dCas9 complex comprises the Alu_trusgRNA or a combination of Alu_trusgRNA and L1_trusgRNA as described in claim 1, and dCas9; (3) preparing a reaction system, wherein the reaction system comprises the nucleic acid sample described in step (1) and the sgRNA-dCas9 complex described in step (2), and reacting in a buffer; (4) Using magnetic beads coated with streptavidin to capture the sgRNA-dCas9 complex and its bound host DNA to form a magnetic bead-protein-RNA-DNA complex; (5) Magnetic separation removes the magnetic bead-protein-RNA-DNA complex, thereby achieving the purpose of removing host DNA from the metagenome.
11. The method according to claim 10, characterized in that The sgRNA-dCas9 complex in step (2) also includes dCas9, 10X NEB buffer, and RNase inhibitor.
12. The method according to claim 11, characterized in that The usage amounts of Alu_trusgRNA, L1_trusgRNA, dCas9, 10X NEB buffer, and RNase inhibitor are (0.1~ 0.5) μg, (0.1~ 0.5) μg, (0.1~ 1) μg, (0.5~ 1.5) μL, and (0.1~ 1) μL, respectively.
13. The method according to claim 12, characterized in that The usage amounts of Alu_trusgRNA, L1_trusgRNA, dCas9, 10X NEB buffer, and RNase inhibitor were 0.25 μg, 0.25 μg, 0.5 μg, 1 μL, and 0.5 μL, respectively.
14. The method according to claim 13, characterized in that The sgRNA-dCas9 complex was supplemented with NFW to 10 μL.
15. The method according to claim 10, characterized in that The composition of the reaction system in step (3) is as follows: nucleic acid sample, sgRNA-dCas9 complex, and 10X NEB buffer.
16. The method according to claim 15, characterized in that The usage amounts of the nucleic acid sample, sgRNA-dCas9 complex, and 10XNEB buffer are (5~15) ng, (0.5~1.5) μL, and (0.5-3.5) μL, respectively.
17. The method according to claim 16, characterized in that The usage amounts of the nucleic acid sample, sgRNA-dCas9 complex, and 10XNEB buffer were 10 ng, 1 μL, and 2 μL, respectively.
18. The method according to claim 17, characterized in that The reaction system was supplemented to 20 μL by adding NFW.
19. The method according to claim 10, characterized in that The magnetic beads coated with streptavidin in step (4) are M-270 streptavidin magnetic beads.
20. Use of the sgRNA of claim 1, the sgRNA-dCas9 complex of claim 2, the reagent of claim 7 or the product of claim 8 in removing host DNA from a metagenome using CRISPR-dCas9.
